CN-121971434-A - Application of 3-indolepropionic acid in preparation of medicine for inhibiting production of pseudomonas aeruginosa virulence factor

Abstract

The invention discloses an application of 3-indolepropionic acid in preparing a medicine for inhibiting the production of pseudomonas aeruginosa virulence factor. The 3-indolepropionic acid inhibits the in-vitro and in-vivo infection of the pseudomonas aeruginosa by inhibiting the quorum sensing of the pseudomonas aeruginosa and the generation of related virulence factors, reduces the death rate of a host, and provides a new treatment strategy for the infection prevention and control of the pseudomonas aeruginosa.

Inventors

• ZHOU YACHUN
• REN ANMIN
• YANG LIANG
• ZHENG WEIDONG
• HUANG XIAOTING
• HE XINXI
• Jia Ashao

Assignees

• 深圳大学

Dates

Publication Date

20260505

Application Date

20260127

Claims (6)

1. Use of 3-indolepropionic acid or a structural approximation thereof for the manufacture of a medicament for inhibiting the production of a virulence factor of pseudomonas aeruginosa, said virulence factor being pyocin, rhamnolipid and/or elastase.
2. 2. The use according to claim 1, wherein the working concentration of 3-indolepropionic acid is not less than 1.89 μg mL -1 .
3. 3. The use according to claim 2, characterized in that the working concentration of 3-indolepropionic acid is 2 μg-mL -1 ,20 μg·mL -1 ,40 μg·mL -1 ,80 μg·mL -1 or 160 μg-mL -1 .
4. 4. The use according to claim 1, wherein the Pseudomonas aeruginosa comprises a Pseudomonas aeruginosa PAO1 strain.
5. 5. A medicament for inhibiting the production of pseudomonas aeruginosa virulence factor, which is characterized in that the active ingredient of the medicament is 3-indolepropionic acid or a structural approximation, and also comprises auxiliary ingredients.
6. 6. The use according to claim 1, wherein the working concentration of 3-indolepropionic acid is not less than 1.89 μg mL -1 .

Description

Application of 3-indolepropionic acid in preparation of medicine for inhibiting production of pseudomonas aeruginosa virulence factor Technical Field The invention belongs to the technical field of medicines, and particularly relates to application of 3-indolepropionic acid in preparation of a medicine for inhibiting production of pseudomonas aeruginosa virulence factor. Background Pseudomonas aeruginosa (Pseudomonas aeruginosa, P.aeromonas) is one of the major pathogenic bacteria worldwide responsible for nosocomial infections and cystic fibrosis. Because of the characteristics of multiple complex pathogenic mechanisms, wide drug resistance and the like, the current clinical treatment of various acute and chronic infections caused by the traditional Chinese medicine is difficult to thoroughly cure. The selection of treatment regimens based on resistance to antibacterial drugs by pseudomonas aeruginosa is particularly difficult and patients with infections often have a high mortality rate. Therefore, research on novel anti-P.aeroginosa drugs and elucidation of the mechanism of new use of the existing drugs for the control and treatment of clinical P.aeroginosa infection are of great significance. Disclosure of Invention The invention aims to provide an application of 3-indolepropionic acid in preparing a medicine for inhibiting the production of pseudomonas aeruginosa virulence factor. The invention provides an application of 3-indolepropionic acid or a structural approximation thereof in preparing a medicine for inhibiting the production of a virulence factor of pseudomonas aeruginosa, wherein the virulence factor is pyocin, rhamnolipid and/or elastase. The 3-indolepropionic acid of the present invention acts primarily by binding to the 3-indolepropionic acid receptor. As a specific embodiment, the 3-indolepropionic acid has a CAS accession number of 830-96-6, a chemical formula of C 11H11NO2 and a molecular weight of 189.214, and the structure of the 3-indolepropionic acid is shown in figure 1. As a preferable mode, the working concentration of the 3-indolepropionic acid is not less than 1.89. Mu.g.mL -1, for example, 2. Mu.g.mL -1,20 μg·mL-1,40 μg·mL-1,80 μg·mL-1 and 160. Mu.g.mL -1, and the effect is more remarkable as the concentration is larger. As a preferred embodiment, the Pseudomonas aeruginosa comprises Pseudomonas aeruginosa PAO1 strain. The invention also provides a medicine for inhibiting the production of the pseudomonas aeruginosa virulence factor, and the effective components of the medicine comprise 3-indolepropionic acid or a structural approximation and auxiliary components. As a preferable scheme, the working concentration of the 3-indolepropionic acid is more than or equal to 1.89 mug.mL -1. The beneficial effects are that: The invention provides an application of 3-indolepropionic acid in preparing a medicine for resisting pseudomonas aeruginosa (Pseudomonas aeruginosa) infection. The 3-indolepropionic acid inhibits the in-vitro and in-vivo infection of the pseudomonas aeruginosa by inhibiting the quorum sensing of the pseudomonas aeruginosa and the generation of related virulence factors, reduces the death rate of a host, and provides a new treatment strategy for the infection prevention and control of the pseudomonas aeruginosa. Drawings FIG. 1 is a block diagram of the molecular formula of 3-indolepropionic acid; FIG. 2 is a graph of experimental results of 3-indolepropionic acid treatment on the fluorescent reporter strain PAO1/lasB-gfp of Pseudomonas aeruginosa pqs quorum sensing systems; FIG. 3 is a graph showing experimental results of 3-indolepropionic acid treatment on the fluorescent reporter strain PAO1/pqsA-gfp of Pseudomonas aeruginosa rhl quorum sensing system; FIG. 4 is a graph showing experimental results of 3-indolopropionic acid treatment of Pseudomonas aeruginosa las quorum sensing fluorescent reporter strain PAO 1/rhlA-gfp; FIG. 5 is a graph showing experimental results of 3-indolepropionic acid inhibiting related virulence factors regulated by the induction of the P.aerobosa population, wherein A is the level of pyocin, B is the level of rhamnolipid, and C is the level of elastase activity; FIG. 6 is a graph showing experimental results of 3-indolepropionic acid in prolonging survival rate of Chilo suppressalis in a P.aerocinosa Chilo suppressalis in vitro infection model; Where "ns" indicates that the difference is not statistically significant, ", indicates that p < 0.00001, the difference is very significant compared to the control group. Detailed Description In order to further illustrate the present invention, the following examples are provided to describe the use of 3-indolepropionic acid according to the present invention in the preparation of medicaments against Pseudomonas aeruginosa infection in detail, but they should not be interpreted as limiting the scope of protection of the present invention. The medicine is 3-indolopropionic acid (IPA), the produ